NEW YORK (GenomeWeb) – British informatics firm Genomics plc today announced a collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust to analyze genomic sequences in rare diseases and cancer.
Under the terms of the agreement, the partners will work on a pilot study to establish genome sequencing as a clinical tool in rare diseases, cancers, and other disorders. Genomics will use its software to analyze up to 500 genome sequences, linking genotypes and phenotypes.
Financial terms of the deal were not disclosed.
"The depth of expertise and time needed to provide accurate interpretation of whole-genome information is a real barrier to its widespread acceptance," Oxford professor Jenny Taylor, the principal investigator of the pilot study, said in a statement. She added that the agreement could move genomic sequencing closer to routine clinical care.
Genomics CEO John Colenutt added that the collaboration would allow Genomics to demonstrate its software's ability to scale up to analyze large databases. The firm is an Oxford University spinout.
The partners said in a statement that the project is supported by the Wellcome Trust and the UK Department of Health.
Earlier this month, Genomics signed a deal to collaborate on drug target screening with Biogen.